Vaccine and Immunotherapy Center, Massachusetts General Hospital-East, Boston, Massachusetts, USA; and.
InnatOss, Oss, The Netherlands.
FASEB J. 2018 Jan;32(1):5-15. doi: 10.1096/fj.201700325R. Epub 2017 Nov 1.
Mass cytometry enables highly multiplexed profiling of cellular immune responses in limited-volume samples, advancing prospects of a new era of systems immunology. The capabilities of mass cytometry offer expanded potential for deciphering immune responses to infectious diseases and to vaccines. Several studies have used mass cytometry to profile protective immune responses, both postinfection and postvaccination, although no vaccine-development program has yet systematically employed the technology from the outset to inform both candidate design and clinical evaluation. In this article, we review published mass cytometry studies relevant to vaccine development, briefly compare immune profiling by mass cytometry to other systems-level technologies, and discuss some general considerations for deploying mass cytometry in the context of vaccine development.-Reeves, P. M., Sluder, A. E., Raju Paul, S., Scholzen, A., Kashiwagi, S., Poznansky, M. C. Application and utility of mass cytometry in vaccine development.
质谱流式细胞术能够在有限体积的样本中对细胞免疫反应进行高度多重分析,为系统免疫学的新时代带来了广阔的前景。质谱流式细胞术的功能为解析传染病和疫苗的免疫反应提供了更大的潜力。已有多项研究使用质谱流式细胞术来分析保护性免疫反应,包括感染后和接种疫苗后的免疫反应,尽管尚无疫苗开发计划从一开始就系统地利用该技术来为候选物设计和临床评估提供信息。在本文中,我们回顾了与疫苗开发相关的已发表的质谱流式细胞术研究,简要比较了质谱流式细胞术与其他系统水平技术的免疫分析,并讨论了在疫苗开发背景下部署质谱流式细胞术的一些一般注意事项。